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insulin in different stages of health care. The background
of the study was that a few sickness insurance funds have
made interface agreements which defined patient referral
up the ladder on the basis of HbA1c levels to improve the
care of diabetes mellitus patients. The study focused on
whether patients under treatment with insulin lispro could
be kept in primary care. The hypothesis was that the
more frequent patients were referred to a specialist or
hospitalized the higher the costs they incur. The explor-
atory study was put together to get some basic costings
from which a hypothesis can be generated for a prospec-
tive naturalistic study. METHODS: A Markov model
was used to estimate the expected costs between the two
therapies. Patients with type 1 and type 2 diabetes melli-
tus were included. Estimates of resource utilization were
obtained from published studies and from an expert panel
of 19 general practitioners (GPs) and diabetologists. Each
expert retrospectively documented the resource utiliza-
tion of three defined patients for each health care level
over a period of one year. Only direct costs were consid-
ered (perspective from statutory health insurances). RE-
SULTS: The results revealed a clear difference of DM
468 in annual costs per patient in favor of insulin lispro
under actual treatment conditions (insulin lispro DM
2,994; regular human insulin DM 3.462). According to
guidelines resulting treatment costs for both cohorts were
roughly identical (insulin lispro DM 3,568, regular hu-
man insulin DM 3,581). CONCLUSION: Based on the
assumptions used in the model, intensive controlled treat-
ment of diabetic patients with insulin lispro under actual
treatment conditions results in lower costs due to a lower
probability of hospitalization and lower GPs treatment
costs, in spite of the initially higher price of insulin lispro.
These differences will be the subject of a prospective co-
hort study with a naturalistic design, testing the main hy-
pothesis whether hospitalization costs can be reduced by
treatment with insulin lispro and whether the patients
can be kept in primary care settings with improved care
and lower costs.
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OBJECTIVE: To identify the impact of Type 2 Diabetes
on Health-related Quality of Life (HrQoL) using the Eu-
roQol (EQ-5D). METHOD: The EQ-5D questionnaire
was sent by post to a random sample of 750 Type 2 Dia-
betes patients at each of 4 UK clinical centres as part of
the T2ARDIS cost of illness survey. The samples were
drawn from registers including patients receiving only
primary care as well as those receiving hospital care. The
impact of complications of Type 2 diabetes on HrQoL
was evaluated. Comparison of the EQ-5D index findings
was made with data from the 1996 Health Survey of En-
gland. RESULTS: A total of 1510 EQ-5D index ques-
tionnaires were returned (50.3%). There was no signifi-
cant response bias, based on checks of non-respondent
demographics and treatment regimes. The T2ARDIS re-
spondents demonstrated significantly more problems (“some
problems” plus “extreme problems”) than the general
population across each of the five domains of the EQ-5D
index. The deficit in HrQoL versus the general popula-
tion was most marked in the 45 age group. The compli-
cations of diabetes were also found to be associated with
reduced HrQoL; pairs of respondents matched for 10
year age group, gender and smoking were identified in
subgroups representing those with no complications, mi-
crovascular complications, macrovascular complications,
and both micro and macrovascular complications (n 
89 in each subgroup). All the complications subgroups
showed significantly lower HrQoL than the subgroup
with no complications (P  0.01 in all cases). The mean
EQ-5D Index scores for the four groups were: none 
0.79, micro  0.7, macro  0.7 and both  0.49. CON-
CLUSION: People with Type 2 Diabetes experience sig-
nificantly lower HrQoL than their peers in the general
population, particularly in the younger age groups. Mi-
crovascular and macrovascular complications are associ-
ated with even lower levels of HrQoL. Prevention of
complications may enhance quality of life in Type 2 diabetes.
GENDER-SPECIFIC DISORDERS
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The loss of hair either due to ageing, pathology or a drug
therapy, often proves to be badly supported by those
who suffer from it. OBJECTIVE: Evaluate the psycho-
logical impact and the consequences on Quality of Life of
hair loss. METHOD: Literature review. RESULTS: This
review confirms that loss of hair has an important psy-
chosocial impact. The lack of self-esteem, emotional re-
actions, frustrations and social inabilities are recurrent
terms. The change of Quality of Life and of satisfaction
develop as much as the degree of hair loss. Subjects with
advanced alopecia report twice as much socio-emotional
effect as those with a mild and/or moderate alopecia.
Women suffer more of anxiety, of low self-estimation
and unsatisfaction of the body image and of their general
Quality of Life. Young people with early hair loss prove
to be more psychologically sensitive. Children are also
vulnerable and some aggressiveness is noticed. A sound
psychological morbidity can be associated to alopecia. It
can induce distress, which, in some cases, changes into a
real depression. Koo has identified, on the basis of DSM-
III-R, near to 9% of major depression within a sampling
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of subjects victims of alopecia. Furthermore, 18.2% suf-
fer from anxiety, 3,5% presented a social phobia and
4,4% paranoia. All these rates are above those noticed
with the general population. CONCLUSION: These dif-
ferent results underline the necessity for assessing the psy-
chological and even psychiatric consequences of hair loss
for patients suffering alopecia. Demonstration is done
that these patients need to have a relevant psychological
help from their practitioners, who are very often them-
selves relying on the outside help of a pharmacological
nature for assisting their work.
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OBJECTIVE: A single course of treatment with Assisted
Reproduction Techniques (ART) may be viewed as in-
complete treatment for the majority of infertile couples.
A realistic comparison of both costs and therapeutic con-
sequences must consider the cumulative costs of achiev-
ing an ongoing pregnancy after several cycles of treat-
ment using Recombinant FSH (rFSH) or urinary FSH
(uFSH). METHOD: A cost-effectiveness analysis included
the Markov model and Monte-Carlo simulations. Infor-
mation on costs and probabilities were provided by na-
tional formulary costs and clinic tariff, a meta-analysis
(of randomized clinical trials), randomized controlled
clinical trials, medical literature and national registries.
All the data were validated by a panel of international ex-
perts. Because estimates for key clinical data will vary de-
pending on the source, the estimates of variability among
the transition probabilities were ratified by the expert
panel according to UK experience. This approach pro-
vided a distribution of transition probabilities from which
a precise standard deviation could be obtained for each
outcome. The final Markov matrix included about 200
health states, computerized with a specific Pascal pro-
gram, which covered the complete ART process includ-
ing both fresh and cryopreserved embryos. RESULTS:
After running 5000 simulations on a virtual population
of 100,000 patients the results are: Total number of suc-
cesses (pregnancy): 40,575 for rFSH and 37,358 for
uFSH. Cost/success: £5906 (SD  £232) for rFSH and
£6060 (SD  £279) for uFSH. Mean number of cycles/
success: 4.59 for rFSH and 5.25 for uFSH. CONCLU-
SION: Recombinant FSH is more effective and more
cost-effective than urinary derived FSH.
PGS3
AN ASSESSMENT OF THE RELATION BETWEEN 
SILDENAFIL USE AND QUALITY OF
LIFE DIMENSIONS
Gasper S1, Macdonald K2
1Pfizer Inc., New York, NY, USA; 2Shachtman-Fagan, Inc., 
Norwalk, CT, USA
OBJECTIVE: To identify the quality of life (QoL) dimen-
sions relevant for men who currently take sildenafil to
treat erectile dysfunction (ED) and to evaluate the impact
of sildenafil use on these QoL dimensions. QoL studies
can be a valuable tool for healthcare decision-makers as
they assess the relative benefits and costs of sildenafil
treatment for ED. METHODS: 500 men taking sildenafil
were interviewed, using a structured questionnaire specif-
ically developed for this study. Each had been diagnosed
with ED by a physician. The respondents were asked to
rate the extent to which sildenafil had affected both phys-
ical and emotional aspects of their life. RESULTS: Fifty-
two percent had been taking sildenafil for more than 1
year. Eighty-six percent of the participants were married.
Of the remaining 14%, 69% reported being in a commit-
ted relationship. The overall results indicate that QoL
measures were high in men receiving sildenafil. The re-
spondents (average age 62) reported that the QoL dimen-
sions where sildenafil had the most impact were confi-
dence, relationship with partner, sex life, and life overall.
Sixty percent reported that they felt more confident after
treating their ED with sildenafil. Eighty-two percent re-
ported an improvement in their relationships with part-
ners; 75% reported an improvement in their sex lives;
and 66% reported an improvement in their overall lives.
CONCLUSION: The results suggest that use of sildenafil
to treat ED has a positive impact on patient’s lives. The re-
sults also suggest that additional investigation into identi-
fying relevant QoL items and domains for ED is war-
ranted since this impact has been undetected by currently
available QoL instruments.
PGS4
PRESENTATION OF THE 23-ITEM WOMEN’S 
HEALTH QUESTIONNAIRE (WHQ): SCORING 
AND INTERPRETATION ISSUES
Girod I1, Keininger DL2, de la Loge C1, Hunter M3
1Mapi Values, Lyon, France; 2Mapi Research Institute, Lyon, 
France; 3St Thomas’ Hospital, London, UK
OBJECTIVE: The scoring of the Women’s Health Ques-
tionnaire (WHQ) was reviewed as part of the Interna-
tional Health-related Quality of Life Database (IQOD)
program. New hypotheses on item grouping were con-
firmed in different translated versions of the WHQ. Using
this new conceptual model, reference values were devel-
oped per country and in different populations. METHODS:
The scoring of the WHQ was reviewed using data from
different countries: UK, US, France, Germany, Italy, Po-
land. The 23-item WHQ measures QoL in women, and
